Advanced

Influence of APOA5 locus on the treatment efficacy of three statins : Evidence from a randomized pilot study in Chinese subjects

Hua, Sha; Ma, Chuanxiang; Zhang, Jun; Li, Jing; Wu, Weiwei; Xu, Ning LU ; Luo, Guanghua and Zhao, Jianrong (2018) In Frontiers in Pharmacology 9(APR).
Abstract

Pharmacogenetics or pharmacogenomics approaches are important for addressing the individual variabilities of drug efficacy especially in the era of precision medicine. One particular interesting gene to investigate is APOA5, which has been repeatedly linked with the inter-individual variations of serum triglycerides. Here, we explored APOA5-statin interactions in 195 Chinese subjects randomized to rosuvastatin (5-10 mg/day), atorvastatin (10-20 mg/day), or simvastatin (40 mg/day) for 12 weeks by performing a targeted genotyping analysis of the APOA5 promoter SNP rs662799 (-1131T > C). There were no significant differences between the treatment arms for any of the statin-induced changes in clinical biomarkers. Reductions in LDL... (More)

Pharmacogenetics or pharmacogenomics approaches are important for addressing the individual variabilities of drug efficacy especially in the era of precision medicine. One particular interesting gene to investigate is APOA5, which has been repeatedly linked with the inter-individual variations of serum triglycerides. Here, we explored APOA5-statin interactions in 195 Chinese subjects randomized to rosuvastatin (5-10 mg/day), atorvastatin (10-20 mg/day), or simvastatin (40 mg/day) for 12 weeks by performing a targeted genotyping analysis of the APOA5 promoter SNP rs662799 (-1131T > C). There were no significant differences between the treatment arms for any of the statin-induced changes in clinical biomarkers. Reductions in LDL cholesterol were influenced by the APOA5 genotype in all three treatment groups. By contrast, changes in HDL cholesterol, and triglycerides were only affected by the APOA5 genotype in the atorvastatin and simvastatin groups and not in the rosuvastatin group. Our results suggest that future studies may need to consider stratifying subjects not only by genetic background but also by prescribed statin type.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
APOA5 genotype, Dyslipidemia, LDL cholesterol, Statins, Triglycerides
in
Frontiers in Pharmacology
volume
9
issue
APR
publisher
Frontiers
external identifiers
  • scopus:85045281646
ISSN
1663-9812
DOI
10.3389/fphar.2018.00352
language
English
LU publication?
yes
id
08ffa3a1-1300-4948-8c33-d06b58a21bb1
date added to LUP
2018-04-25 16:38:30
date last changed
2019-02-20 11:15:17
@article{08ffa3a1-1300-4948-8c33-d06b58a21bb1,
  abstract     = {<p>Pharmacogenetics or pharmacogenomics approaches are important for addressing the individual variabilities of drug efficacy especially in the era of precision medicine. One particular interesting gene to investigate is APOA5, which has been repeatedly linked with the inter-individual variations of serum triglycerides. Here, we explored APOA5-statin interactions in 195 Chinese subjects randomized to rosuvastatin (5-10 mg/day), atorvastatin (10-20 mg/day), or simvastatin (40 mg/day) for 12 weeks by performing a targeted genotyping analysis of the APOA5 promoter SNP rs662799 (-1131T &gt; C). There were no significant differences between the treatment arms for any of the statin-induced changes in clinical biomarkers. Reductions in LDL cholesterol were influenced by the APOA5 genotype in all three treatment groups. By contrast, changes in HDL cholesterol, and triglycerides were only affected by the APOA5 genotype in the atorvastatin and simvastatin groups and not in the rosuvastatin group. Our results suggest that future studies may need to consider stratifying subjects not only by genetic background but also by prescribed statin type.</p>},
  articleno    = {352},
  author       = {Hua, Sha and Ma, Chuanxiang and Zhang, Jun and Li, Jing and Wu, Weiwei and Xu, Ning and Luo, Guanghua and Zhao, Jianrong},
  issn         = {1663-9812},
  keyword      = {APOA5 genotype,Dyslipidemia,LDL cholesterol,Statins,Triglycerides},
  language     = {eng},
  month        = {04},
  number       = {APR},
  publisher    = {Frontiers},
  series       = {Frontiers in Pharmacology},
  title        = {Influence of APOA5 locus on the treatment efficacy of three statins : Evidence from a randomized pilot study in Chinese subjects},
  url          = {http://dx.doi.org/10.3389/fphar.2018.00352},
  volume       = {9},
  year         = {2018},
}